Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-2.75% $3.18
America/New_York / 21 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 185.19 mill |
EPS: | -15.33 |
P/E: | -0.210 |
Earnings Date: | Mar 25, 2024 |
SharesOutstanding: | 58.24 mill |
Avg Daily Volume: | 0.0410 mill |
RATING 2024-03-21 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.210 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -0.210 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.25 (2.31%) $0.0735 |
Date: 2024-03-27 |
Expected Trading Range (DAY) |
---|
$ 21.11 - 23.41 ( +/- 5.16%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-28 | Drapkin Kimberlee C | Buy | 40 000 | Stock Option (right to buy) |
2023-07-28 | Drapkin Kimberlee C | Buy | 0 | |
2023-07-19 | Viney Joanne L. | Buy | 20 000 | Stock Option (right to buy) |
2023-07-19 | Porteus Matthew | Buy | 20 000 | Stock Option (right to buy) |
2023-07-19 | Karsen Perry A | Buy | 20 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 97 transactions |
Buy: 36 276 632 | Sell: 68 481 989 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.18 (-2.75% ) |
Volume | 0.299 mill |
Avg. Vol. | 0.0410 mill |
% of Avg. Vol | 731.06 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.